What is ADAMTS13 (A Disintegrin And Metalloproteinase with Thrombospondin motifs 13) activity?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 19, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

What is ADAMTS13 Activity?

ADAMTS13 activity refers to the functional capacity of the ADAMTS13 metalloprotease enzyme to cleave ultra-large von Willebrand factor (UL-VWF) multimers in the bloodstream, with normal activity levels around 100% (or 100 IU/dL) and severe deficiency defined as <10% activity. 1

Biological Function and Mechanism

ADAMTS13 (A Disintegrin And Metalloproteinase with ThromboSpondin type 1 motifs, member 13) is a zinc-containing metalloprotease produced primarily by hepatic stellate cells and likely endothelial cells. 1 Once released into circulation, it performs a critical regulatory function:

  • Cleaves a single peptide bond (Tyr1605-Met1606) in the central A2 domain of VWF molecules 2
  • Reduces the size of ultra-large VWF multimers that would otherwise accumulate on endothelial surfaces and in circulating blood 1
  • Prevents excessive platelet adhesion and aggregation that leads to microvascular thrombosis 1
  • Regulates hemostasis and inflammatory responses through this proteolytic activity 1

Clinical Significance of ADAMTS13 Activity Levels

Severe Deficiency (<10% activity)

When plasma ADAMTS13 activity falls below 10 IU/dL (or 10% of normal), the diagnosis of thrombotic thrombocytopenic purpura (TTP) should be considered in the proper clinical context. 1 This threshold has:

  • 97% sensitivity and 100% specificity for TTP diagnosis 3
  • Leads to accumulation of UL-VWF multimers
  • Triggers microvascular thrombus formation throughout the body
  • Results in ischemic organ damage and potential mortality 1

Moderate Deficiency

Moderate ADAMTS13 deficiency may occur in:

  • Complement-mediated hemolytic uremic syndrome (HUS)
  • Sepsis
  • Autoimmune conditions 3

These conditions can have prothrombotic and proinflammatory consequences even without reaching the severe deficiency threshold. 4

Causes of ADAMTS13 Deficiency

Immune-mediated (iTTP)

  • Autoantibodies against ADAMTS13 1
  • Most common form of TTP
  • Detectable anti-ADAMTS13 IgG antibodies (though may be absent initially) 1

Congenital (cTTP)

  • Mutations in the ADAMTS13 gene (approximately 250 causative mutations identified) 1
  • Autosomal recessive inheritance
  • Results in either impaired secretion or non-functional protease 1

Laboratory Testing Considerations

The sample for ADAMTS13 activity testing must be drawn before the first therapeutic plasma exchange (TPE) session. 3 If this is not possible, a sample obtained the next day just before the next TPE session remains useful. 3

Important Testing Caveats:

  • No single test is fully reliable - if ADAMTS13 activity >10% is found in a patient with suggestive clinical picture, further assays using different techniques should be performed 3
  • Falsely low results are the most frequent challenge with automated or semi-quantitative assays 3
  • When results seem discordant with clinical presentation, a FRET assay should be obtained 3
  • Various assay platforms exist including flow cytometric methods, ELISA-based assays, and other functional assays 5, 6

Beyond TTP: Broader Clinical Relevance

ADAMTS13 activity has implications beyond TTP diagnosis:

  • Thrombotic microangiopathies (TMAs) in general 4
  • Ischemic stroke and coronary artery disease risk assessment 4
  • COVID-19 and severe infections (relative ADAMTS13 deficiency may contribute to thrombosis risk) 6
  • Cancer and other prothrombotic states 6

The measurement of ADAMTS13 activity has evolved from labor-intensive methods to rapid, automated platforms, improving clinical decision-making by shortening diagnostic uncertainty and supporting earlier differentiation of TTP from other TMAs. 7

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.